Literature DB >> 12050374

Characterization of producer cell-dependent restriction of murine leukemia virus replication.

Fatima Serhan1, Nathalie Jourdan, Sylvie Saleun, Philippe Moullier, Ghislaine Duisit.   

Abstract

We previously reported that the human bronchocarcinoma cell line A549 produces poorly infectious gibbon ape leukemia virus-pseudotyped Moloney murine leukemia virus (MLV). In contrast, similar amounts of virions recovered from human fibrosarcoma HT1080 cells result in 10-fold-higher transduction rates (G. Duisit, A. Salvetti, P. Moullier, and F. Cosset, Hum. Gene Ther. 10:189-200, 1999). We have now extended this initial observation to other type-C envelope (Env) pseudotypes and analyzed the mechanism involved. Structural and morphological analysis showed that viral particles recovered from A549 (A549-MLV) and HT1080 (HT1080-MLV) cells were normal and indistinguishable from each other. They expressed equivalent levels of mature Env proteins and bound similarly to the target cells. Furthermore, incoming particles reached the cytosol and directed the synthesis of linear viral DNA equally efficiently. However, almost no detectable circular DNAs could be detected in A549-MLV-infected cells, indicating that the block of infection resulted from defective nuclear translocation of the preintegration complex. Interestingly, pseudotyping of A549-MLV with vesicular stomatitis virus glycoprotein G restored the amount of circular DNA forms as well as the transduction rates to HT1080-MLV levels, suggesting that the postentry blockage could be overcome by endocytic delivery of the core particles downstream of the restriction point. Thus, in contrast to the previously described target cell-dependent Fv-1 (or Fv1-like) restriction in mammalian cells (P. Pryciak and H. E. Varmus, J. Virol. 66:5959-5966, 1992; G. Towers, M. Bock, S. Martin, Y. Takeuchi, J. P. Stoye, and O. Danos, Proc. Natl. Acad. Sci. USA 97:12295-12299, 2000), we report here a new restriction of MLV replication that relies only on the producer cell type.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12050374      PMCID: PMC136263          DOI: 10.1128/jvi.76.13.6609-6617.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  74 in total

1.  Characterization of intracellular reverse transcription complexes of human immunodeficiency virus type 1.

Authors:  A Fassati; S P Goff
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  Human immunodeficiency virus type 1 Nef functions at the level of virus entry by enhancing cytoplasmic delivery of virions.

Authors:  E Schaeffer; R Geleziunas; W C Greene
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

3.  Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A.

Authors:  C Aiken
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 4.  Structure and function of the WW domain.

Authors:  M Sudol
Journal:  Prog Biophys Mol Biol       Date:  1996       Impact factor: 3.667

5.  RNA trafficking signals in human immunodeficiency virus type 1.

Authors:  A J Mouland; H Xu; H Cui; W Krueger; T P Munro; M Prasol; J Mercier; D Rekosh; R Smith; E Barbarese; E A Cohen; J H Carson
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

6.  Use of helper-free replication-defective simian immunodeficiency virus-based vectors to study macrophage and T tropism: evidence for distinct levels of restriction in primary macrophages and a T-cell line.

Authors:  S S Kim; X J You; M E Harmon; J Overbaugh; H Fan
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

7.  Cytoskeletal proteins inside human immunodeficiency virus type 1 virions.

Authors:  D E Ott; L V Coren; B P Kane; L K Busch; D G Johnson; R C Sowder; E N Chertova; L O Arthur; L E Henderson
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

8.  Fine mapping and characterization of the Rous sarcoma virus Pr76gag late assembly domain.

Authors:  Y Xiang; C E Cameron; J W Wills; J Leis
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

9.  Role of Vif in human immunodeficiency virus type 1 reverse transcription.

Authors:  J Goncalves; Y Korin; J Zack; D Gabuzda
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

10.  Equine infectious anemia virus utilizes a YXXL motif within the late assembly domain of the Gag p9 protein.

Authors:  B A Puffer; L J Parent; J W Wills; R C Montelaro
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

View more
  3 in total

1.  As(2)O(3) enhances retroviral reverse transcription and counteracts Ref1 antiviral activity.

Authors:  Lionel Berthoux; Greg J Towers; Cagan Gurer; Paolo Salomoni; Pier Paolo Pandolfi; Jeremy Luban
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

2.  Lv2, a novel postentry restriction, is mediated by both capsid and envelope.

Authors:  Christian Schmitz; David Marchant; Stuart J D Neil; Keith Aubin; Sandra Reuter; Matthias T Dittmar; Aine McKnight
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

3.  Early detection of a two-long-terminal-repeat junction molecule in the cytoplasm of recombinant murine leukemia virus-infected cells.

Authors:  Fatima Serhan; Magalie Penaud; Caroline Petit; Thierry Leste-Lasserre; Stéphane Trajcevski; David Klatzmann; Ghislaine Duisit; Pierre Sonigo; Philippe Moullier
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.